



Announcement Summary

Entity name

MEDIBANK PRIVATE LIMITED

Date of this announcement

Thursday December 09, 2021

The +securities the subject of this notification are:

☒ +Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

Total number of +securities to be issued/transferred

ASX +security code	Security description	Total number of +securities to be issued/transferred	Issue date
MPLAA	PERFORMANCE RIGHTS	3,542,600	03/12/2021

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

MEDIBANK PRIVATE LIMITED

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

1.2 Registered number type

ABN

Registration number

47080890259

1.3 ASX issuer code

MPL

1.4 The announcement is

☒ New announcement

1.5 Date of this announcement

9/12/2021



Part 2 - Issue details

2.1 The +securities the subject of this notification are:

☒ +Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

☒ has an existing ASX security code ("existing class")



Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B

ASX +security code and description

MPLAA : PERFORMANCE RIGHTS

Date the +securities the subject of this notification were issued

3/12/2021

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class☒ Yes**Were any of the +securities issued to +key management personnel (KMP) or an +associate?**☒ Yes**Provide details of the KMP or +associates being issued +securities.**

Name of KMP	Name of registered holder	Number of +securities
David Koczkar	David Koczkar	821,636
Milosh Milisavljevic	Milosh Milisavljevic	161,980
Mark Rogers	Mark Rogers	302,147
Andrew Wilson	Andrew Wilson	300,989

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

https://www.medibank.com.au/content/dam/retail/about-assets/pdfs/investor-centre/annual-reports/Medibank_AR2021_website.pdf
https://www.medibank.com.au/content/dam/retail/about-assets/pdfs/investor-centre/annual-general-meeting/Medibank_NoM2021.pdf

Any other information the entity wishes to provide about the +securities the subject of this notification

The grant of performance rights comprises performance rights issued as part of the FY21 Deferred Short Term Incentive (STI), and FY22 Long Term Incentive (LTI). The breakdown of these performance rights for KMP is as follows:

- David Koczkar: FY21 Deferred STI - 102,787 Performance Rights; FY22 LTI - 718,849 Performance Rights. The grant of LTI to David Koczkar was approved by shareholders at Medibank's 2021 Annual General Meeting;
- Milosh Milisavljevic: FY22 LTI - 161,980 Performance Rights;
- Mark Rogers: FY21 Deferred STI - 94,480 Performance Rights; FY22 LTI - 207,667 Performance Rights
- Andrew Wilson: FY21 Deferred STI - 93,322 Performance Rights; FY22 LTI - 207,667 Performance Rights



Issue details

Number of +securities
3,542,600

Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this application, the +securities of the entity will comprise:
(A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one application for quotation/issuance currently with ASX for processing.)

4.1 Quoted +Securities (Total number of each +class of +securities quoted)

ASX +security code and description	Total number of +securities on issue
MPL : ORDINARY FULLY PAID	2,754,003,240

4.2 Unquoted +Securities (Total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
MPLAA : PERFORMANCE RIGHTS	8,148,218



Part 5 - Other Listing Rule requirements

5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?

☒ No

5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1?

☒ No

5.2b Are any of the +securities being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

☒ Yes

5.2b.1 How many +securities are being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

2,823,751

5.2c Are any of the +securities being issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?

☒ No